Sunshine Act Compliance
Disclaimer: This document is not intended to provide legal advice. For legal advice concerning the Federal Physician Payment Sunshine Statute, please consult your institution or legal counsel.
For more information, please send an email to sunshinequestions-d@gene.com.
| Question | Answer |
|---|---|
Reportable period start date |
CMS issued the Sunshine Act final rule on February 1, 2013, and established August 1, 2013 as the start date for data collection. |
Report due to government |
The first report - on August 1 - December 31, 2013 data - will be due March 31, 2014. |
Government Publication Date |
CMS will release the data publicly by September 30, 2014. |
Required Reporting Entities |
APPLICABLE GROUP PURCHASING ORGANIZATIONThe term 'applicable group purchasing organization' means a group purchasing organization (as defined by the Secretary) that purchases, arranges for, or negotiates the purchase of a covered drug, device, biological, or medical supply which is operating in the United States, or in a territory, possession, or commonwealth of the United States. APPLICABLE MANUFACTURERThe term 'applicable manufacturer' means a manufacturer of a covered drug, device, biological, or medical supply which is operating in the United States, or in a territory, possession, or commonwealth of the United States. |
Definition of Covered Products |
COVERED DEVICEThe term 'covered device' means any device for which payment is available under title XVIII or a State plan under title XIX or XXI (or a waiver of such a plan). COVERED DRUG, DEVICE, BIOLOGICAL, OR MEDICAL SUPPLYThe term 'covered drug, device, biological, or medical supply' means any drug, biological product, device, or medical supply for which payment is available under title XVIII or a State plan under title XIX or XXI (or a waiver of such a plan) |
Information Requirements in the Disclosure |
|
Specific Payment Types Which Must be Reported |
|
Covered People and Entities |
|
Excluded from Reporting |
A transfer of anything of value which is less than $10, unless the aggregate amount transferred to, requested by, or designated on behalf of the covered recipient by the applicable manufacturer during the calendar year exceeds $100.
|
Clinical Development Investigations |
Reportable, but not required to publicly disclose until either:
|
Penalties |
Failure to report subject to a penalty of not less than $1,000, but not more than $10,000 for each payment or other transfer of value not reported. The total civil penalty will not exceed $150,000 per calendar year. Knowingly failing to submit payment data results in a penalty of not less than $10,000, but not more than $100,000, for each payment. Penalty will not exceed $1,000,000 per calendar year. |
State law preemption |
All state laws that impose the same reporting requirements are pre-empted by this law. State laws that impose different reporting or prohibition provisions shall continue to be effective. |
